Breast Cancer

Troy Bremer, PhD, chief scientific officer at PreludeDx, discusses biosignature model and it's potential in predicting radiation therapy response for those with early-stage invasive breast cancer.

Almost 80% of patients have now stopped treatment with ribociclib, but benefit persists and is greater than it was 6 months ago, according to the presenter.

Study results indicate insignificant differences between PFS and OS in patients with HR[+]/HER2[-] breast cancer who received either palbociclib-letrozole or palbociclib-fulvestrant treatment.

In an interview at the 2023 San Antonio Breast Cancer Symposium, Ana Ferrigno Guajardo, MD, discussed research into the safety and efficacy of taxane-based chemotherapy use in pregnant patients with breast cancer.

As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.

Gabriel N. Hortobagyi, MD, MACP, FASCO, a professor at the University of Texas MD Anderson Cancer Center, discussed the final data on invasive disease-free survival from the NATALEE trial of ribociclib in combination with a nonsteroid aromatase inhibitor (NSAI).

Mara Hofherr, PharmD, a clinical oncology pharmacist at Washington University, highlights key findings of the KEYNOTE-522 trial in comparison of outcomes between Black and White patients with triple-negative breast cancer.

Gabriel Hortobagyi, MD, FACP, professor and chair emeritus of the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center discusses the changes in breast cancer management over the past decade.

Amelie G. Ramirez, DrPH, MPH, director of the Institute for Health Promotion Research at UT Health Science Center San Antonio, discussed the need for standardized questionnaires for clinicians to discuss social determinants of health with their oncology patients.

The discussion delves into the results and implications of the clinical trials, shedding light on the efficacy and safety profile of this combination therapy.

Improvements in PFS were also seen among patients with brain metastases.

pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.

MONARCH 3 final OS data show that the combination of abemaciclib and a NSAI in the first-line resulted in numerically longer OS compared to an NSAI alone.

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.

The investigational combination also delayed the median time to first chemotherapy in all age groups.

Patients with breast cancer who underwent chemotherapy and skipped RNI did not face an increased risk of disease recurrence or death 5 years post-surgery.

Although PFS was improved in patients with unresectable locally advanced or metastatic HER2-positive breast cancer, OS data were immature, requiring further research.

Mridula George discusses the role of personalized circulating tumor DNA monitoring in predicting the response to neoadjuvant therapy for early-stage breast cancer.

Trastuzumab deruxtecan and elacestrant both represent important new treatment options for subgroups of patients with breast cancer.

In the first-line setting, inavolisib plus palbociclib and fulvestrant improved PFS in patients with HR-positive breast cancers; however, further research is needed to understand the trends in OS.

Pharmacy Times will be covering the 2023 San Antonio Breast Cancer Symposium (SABCS), happening December 5 through 9 in Texas.

Further research is necessary to better understand the development and factors that contribute to CBC after PBC treatment.

In addition to predicting breast cancer outcomes, the AI tool can help determine effective treatment options in patients, sparing them from unnecessary treatments.

The investigators note that continued support during breast cancer treatment is necessary for patient comfort beyond diagnosis and the initial phases of treatment.

TcdBFBD, derived from a toxin found in Clostridium difficile, was tested in mouse models that mimicked different subtypes of breast cancer.

The study findings indicate that health care professionals significantly underreport symptoms compared to patients with breast cancer, with reported comorbidities varying.

Capivasertib is indicated for hormone receptor-positive, human epidermal growth factor 2-negative locally advanced or metastatic breast cancer with 1 or more PIK3CA/ALT1/PTEN-alterations.

With their final thoughts, the panelists provide key takeaways from their conversation regarding CDK4/6 inhibitor therapy in treatment of HR+/HER2- metastatic breast cancer.